Fluvoxamine Shows Promise in Mitigating Fatigue Associated with Long COVID
A randomized clinical trial indicates that the antidepressant fluvoxamine may significantly reduce fatigue and improve quality of life for patients with long-standing post-viral symptoms.
A recent clinical study has identified a potential therapeutic intervention for one of the most debilitating symptoms of post-acute sequelae of SARS-CoV-2 (PASC). According to research findings shared via ScienceDaily, the antidepressant medication fluvoxamine has demonstrated efficacy in reducing the persistent, crushing fatigue that characterizes long COVID.
The randomized controlled trial involved 399 adult participants who were monitored to assess the impact of the drug compared to a placebo. Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) commonly used to treat obsessive-compulsive disorder and depression, was found to significantly improve the energy levels and overall quality of life of those in the treatment group. These results position the medication as one of the first pharmacological options to provide measurable relief for the chronic exhaustion that frequently follows initial COVID-19 infection.
While the exact mechanism of action in this context requires further investigation, researchers suggest that fluvoxamine's anti-inflammatory properties may play a role. Specifically, the drug interacts with the sigma-1 receptor, which can modulate the body’s inflammatory response—a pathway suspected to be dysregulated in long COVID patients. Because fluvoxamine is an established, low-cost generic medication, these findings offer a scalable and accessible pathway for clinical management of PASC.
Despite the positive outcomes, experts emphasize that larger-scale longitudinal studies are necessary to confirm these effects across diverse populations and to determine optimal dosing strategies. For now, however, the study provides a critical scientific foundation for addressing a condition that has impacted millions of individuals worldwide. This breakthrough marks a significant step forward in neuro-immunological research and the ongoing effort to mitigate the long-term societal and medical impacts of the pandemic.
Source: ScienceDaily / Mind & Brain: Common antidepressant may ease long COVID’s crushing fatigue (July 2026).
Quick answers
- What is fluvoxamine and how does it help with long COVID?
- Fluvoxamine is an antidepressant that may reduce long COVID fatigue by modulating the body's inflammatory response through sigma-1 receptor interaction.
- Was the fluvoxamine study peer-reviewed or randomized?
- The study was conducted as a randomized clinical trial involving 399 adults to ensure data reliability against a placebo group.
- Is fluvoxamine an expensive treatment for long COVID?
- No, it is characterized as a low-cost, widely available generic medication, making it an accessible option for large-scale treatment.
Rewritten by Zeit editorial AI. Based on original reporting at ScienceDaily — Mind & Brain.